RecruitingPhase 1Phase 2NCT06713499

A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis

A Phase Ib/II Study to Investigate the Safety、PK and PD of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd

Enrollment

50 participants

Start Date

Dec 18, 2024

Study Type

INTERVENTIONAL

Conditions

Children and Adolescents With Moderate-to-severe Atopic Dermatitis

Summary

This trial was designed to evaluate the safety of SHR-1819 in children and adolescents with moderate-to-severe atopic dermatitis.

Eligibility

Min Age: 6 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SHR-1819 injection for people with children and adolescents with moderate-to-severe atopic dermatitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 6 Years to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSHR-1819 injection

SHR-1819 injection.

Locations(1)

The First Affiliated Hospital of China Medical University

Shenyang, Liaoning, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06713499